Tirzepatide has a shorter half-life of approximately five days compared to semaglutide at seven days
Women may experience changes in cycle timing, flow intensity, missed periods, or breakthrough bleeding as the body adjusts to new metabolic parameters
Liraglutide, injectable semaglutide, and dulaglutide have shown statistically significant reductions in major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors
This medication works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways
Pool of Placebo- and Active-Controlled Trials The occurrence of adverse reactions was also evaluated in a larger pool of patients with type 2 diabetes participating in 7 placebo- and active-controlled glycemic control trials [see Clinical Studies (14)] including two trials in Japanese patients evaluating the use of OZEMPIC as monotherapy and add-on therapy to oral medications or insulin